

Rosemont Pharmaceuticals

ABPI Disclosure 2023- Methodological Notes

General summary

All values are in British Pounds Sterling

All HCPs and HCOs are UK based and therefore there are no implications regarding tax, currency nor cross border payments.

Payments to HCPs: Exclude VAT as they were not VAT registered

Payments to HCO: Exclude VAT

Calculation of FMV

When requesting the services of HCPs and HCOs Rosemont maintain a standard fair market value (FMV) methodology to ensure consistency. FMV compensation is driven by three factors; FMV rates, a robust tiering model and activity fees.

Contracts are compiled prior to any activity which clearly defines the arrangements and expected outputs of the engagements.

HCPs

Rosemont selects HCPs to engage with, in accordance with their relevant expertise and capability.

5 HCPs were engaged during 2023 and all 'fees' are for work undertaken on our behalf including speaking engagements.

HCOs

Rosemont are happy to provide an overview regarding the activities that we have undertaken with HCOs during 2023.

The engagements consist of 'sponsorship agreements' which included supporting exhibitions, conferences, education, and general activities. 'Fees for contracted services' include marketing activities targeted to memberships.



Lucis Pharmaceuticals Ltd

Rosemont Pharmaceuticals acquired Lucis Pharmaceuticals Ltd 14th June 2023. Lucis did not undertake any transfers of value with HCPs or HCOs during the 2023 period.